Antithrombotic drugs for carotid artery dissection

Area of Science:

• Neurology
• Vascular Medicine
• Clinical Trials

Background:

• Extracranial internal carotid artery dissection (eICAD) is a primary cause of stroke in younger individuals.
• Effective treatment strategies for eICAD are crucial for preventing stroke and improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of anticoagulants versus antiplatelet agents in patients with eICAD.
• To compare the risks of ischemic stroke and major bleeding between anticoagulant and antiplatelet therapies.
• To determine if these treatments offer better functional outcomes compared to no treatment.

Main Methods:

• Systematic review of randomized controlled trials, controlled clinical trials, and observational studies.
• Searches conducted across major databases including Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE, and EMBASE.
• Data extraction focused on primary outcomes (death, death or disability) and secondary outcomes (ischemic stroke, hemorrhage).

Main Results:

• No completed randomized trials were identified for comparing antithrombotic treatments with control.
• Observational studies (1285 patients) comparing antiplatelets and anticoagulants showed no significant differences in death or ischemic stroke.
• A non-significant trend favored anticoagulants for death or disability, with imprecise estimates for bleeding events.

Conclusions:

• Current evidence from randomized trials is insufficient to support the routine use of anticoagulants or antiplatelet agents for eICAD.
• Non-randomized studies do not demonstrate a significant difference in efficacy or safety between anticoagulants and antiplatelet agents for eICAD.